C2 therapeutic drug monitoring of cyclosporine:: Sources of variability

被引：7

作者：

Billaud, EM ^{[1
]}

Antoine, C ^{[1
]}

机构：

[1] Hop Georges Pompidou, Serv Pharmacol, F-75908 Paris 15, France

来源：

TRANSPLANTATION PROCEEDINGS | 2002年 / 34卷 / 07期

关键词：

D O I：

10.1016/S0041-1345(02)03519-4

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：2828 / 2830

页数：3

共 15 条

[1]

Barama A, 2000, TRANSPLANTATION, V69, pS162

[2] Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients [J].

Belitsky, P ;

Dunn, S ;

Johnston, A ;

Levy, G .

CLINICAL PHARMACOKINETICS, 2000, 39 (02) :117-125

[3] Neoral absorption profiling: An evolution in effectiveness [J].

Belitsky, P ;

Levy, GA ;

Johnston, A .

TRANSPLANTATION PROCEEDINGS, 2000, 32 (3A) :45S-52S

[4]

COLE E, 2001, AM J TRANSPLANT, V1, P386

[5] Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection -: Results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8) [J].

Grant, D ;

Kneteman, N ;

Tchervenkov, J ;

Roy, A ;

Murphy, G ;

Tan, A ;

Hendricks, L ;

Guilbault, N ;

Levy, G .

TRANSPLANTATION, 1999, 67 (08) :1133-1137

[6] Pharmacokinetic validation of neoral absorption profiling [J].

Johnston, A ;

David, OJ ;

Cooney, GF .

TRANSPLANTATION PROCEEDINGS, 2000, 32 (3A) :53S-56S

[7]

JOHNSTON A, 1990, TRANSPLANT P, V22, P1345

[8] Variable oral absorption of cyclosporine - A biopharmaceutical risk factor for chronic renal, allograft rejection [J].

Kahan, BD ;

Welsh, M ;

Schoenberg, L ;

Rutzky, LP ;

Katz, SM ;

Urbauer, DL ;

VanBuren, CT .

TRANSPLANTATION, 1996, 62 (05) :599-606

[9]

KEOWN PA, IN PRESS TRANSPLANTA

[10]

Levy GA, 2000, TRANSPLANTATION, V69, pS387

← 1 2 →